EP3307766A4 - Protéine d'interleukine-7 modifiée et ses utilisations - Google Patents

Protéine d'interleukine-7 modifiée et ses utilisations Download PDF

Info

Publication number
EP3307766A4
EP3307766A4 EP16807859.0A EP16807859A EP3307766A4 EP 3307766 A4 EP3307766 A4 EP 3307766A4 EP 16807859 A EP16807859 A EP 16807859A EP 3307766 A4 EP3307766 A4 EP 3307766A4
Authority
EP
European Patent Office
Prior art keywords
protein
modified interleukin
interleukin
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16807859.0A
Other languages
German (de)
English (en)
Other versions
EP3307766A1 (fr
Inventor
Se Hwan Yang
Donghoon Choi
Hye Seong LIM
Young Chul Sung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genexine Inc
Original Assignee
Genexine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genexine Inc filed Critical Genexine Inc
Publication of EP3307766A1 publication Critical patent/EP3307766A1/fr
Publication of EP3307766A4 publication Critical patent/EP3307766A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16807859.0A 2015-06-11 2016-06-10 Protéine d'interleukine-7 modifiée et ses utilisations Pending EP3307766A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150082793 2015-06-11
PCT/KR2016/006214 WO2016200219A1 (fr) 2015-06-11 2016-06-10 Protéine d'interleukine-7 modifiée et ses utilisations

Publications (2)

Publication Number Publication Date
EP3307766A1 EP3307766A1 (fr) 2018-04-18
EP3307766A4 true EP3307766A4 (fr) 2019-06-12

Family

ID=57503574

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16807859.0A Pending EP3307766A4 (fr) 2015-06-11 2016-06-10 Protéine d'interleukine-7 modifiée et ses utilisations

Country Status (9)

Country Link
US (3) US10208099B2 (fr)
EP (1) EP3307766A4 (fr)
JP (3) JP2018518955A (fr)
KR (3) KR101873201B1 (fr)
CN (2) CN114853873B (fr)
CA (1) CA2986388C (fr)
HK (1) HK1256149A1 (fr)
RU (1) RU2708160C2 (fr)
WO (1) WO2016200219A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1256149A1 (zh) * 2015-06-11 2019-09-13 格纳西尼有限公司 经修饰的白细胞介素-7蛋白及其用途
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
US11357827B2 (en) 2015-12-04 2022-06-14 Genexine, Inc. Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein
US11708399B2 (en) * 2015-12-04 2023-07-25 Genexine, Inc. Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases
BR112019019941B1 (pt) * 2017-03-27 2023-12-05 Noile-Immune Biotech, Inc Polinucleotídeo compreendendo uma sequência de base que codifica o receptor de antígeno quimérico, vetor e método
WO2018215937A1 (fr) * 2017-05-24 2018-11-29 Novartis Ag Protéines à greffe de cytokine-anticorps anti-interleukine-7 et procédés d'utilisation dans le traitement du cancer
KR102038040B1 (ko) * 2017-10-23 2019-10-30 주식회사 프로젠 경피 전달율이 향상된 변형된 egf 단백질, 이를 유효성분으로 포함하는 피부 상태 개선용 화장료 조성물 및 피부질환 예방 또는 치료용 약학 조성물
KR20190045081A (ko) * 2017-10-23 2019-05-02 주식회사 프로젠 변형된 egf 단백질 및 이를 유효성분으로 포함하는 피부 상태 개선용 화장료 조성물
MY209615A (en) * 2018-01-08 2025-07-24 Gi Innovation Inc Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same
AU2019219200B2 (en) * 2018-02-12 2025-02-13 BioNTech SE Treatment using cytokine encoding RNA
EP3830114A4 (fr) * 2018-07-31 2022-08-03 Washington University Utilisation de l'interleukine-7 et de cellules effectrices immunitaires porteuses du récepteur antigénique chimérique (car) pour traiter une tumeur
CA3119341A1 (fr) * 2018-11-16 2020-05-22 Neoimmunetech, Inc. Methode de traitement d'une tumeur au moyen de l'association de la proteine il-7 et d'un inhibiteur de point de controle immunitaire
EP3995508A4 (fr) * 2019-05-14 2023-09-27 Progen Co., Ltd. Nouvelle protéine de fusion fc d'immunoglobuline modifiée et utilisation associée
EP3969119A1 (fr) * 2019-05-17 2022-03-23 Xencor, Inc. Protéines de fusion il-7-fc
MX2022000285A (es) 2019-07-08 2022-02-03 Gi Innovation Inc Dimero de polipeptido con alto contenido de acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige y composicion farmaceutica que comprende el mismo.
CA3146948A1 (fr) * 2019-09-04 2021-03-11 Young Chul Sung Methode permettant d'augmenter la numeration lymphocytaire en utilisant une proteine de fusion d'il-7 dans des tumeurs
AU2020383176B2 (en) * 2019-11-15 2023-10-19 Genexine, Inc. Fusion protein including modified interleukin-7 and TGF beta receptor II and use thereof
KR102400884B1 (ko) * 2019-11-15 2022-05-23 주식회사 제넥신 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
AU2021207586A1 (en) 2020-01-13 2022-07-21 Neoimmunetech, Inc. Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
US20210324027A1 (en) * 2020-04-16 2021-10-21 Genexine, Inc. Modified interleukin-7 proteins and uses thereof
CN111848813A (zh) * 2020-06-04 2020-10-30 泰州市百英生物科技有限公司 一种IL7-Fc-GMCSF融合蛋白及其应用
WO2022093718A1 (fr) 2020-10-26 2022-05-05 Neoimmunetech, Inc. Procédés d'induction de la mobilisation de cellules souches
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
JP2023549112A (ja) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
WO2023085882A1 (fr) * 2021-11-12 2023-05-19 주식회사 제넥신 Thérapie par administration d'une protéine de fusion de l'interleukine-7 pour le traitement ou la prévention d'une maladie infectieuse à coronavirus
CN119836296A (zh) 2021-12-30 2025-04-15 新免疫技术有限公司 用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
KR20240163103A (ko) 2022-03-10 2024-11-18 주식회사 제넥신 두경부암 치료를 위한 삼중 복합약물 투여요법
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法
US20240424127A1 (en) 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
KR20260033048A (ko) 2023-07-03 2026-03-10 네오이뮨텍, 인코퍼레이티드 이종이합체 fc 분자 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314415B1 (fr) * 1987-10-26 1994-08-10 Immunex Corporation Interleukine-7
EP0877752A1 (fr) * 1996-01-23 1998-11-18 The Board Of Trustees Of The Leland Stanford Junior University Procedes servant a rechercher par criblage des peptides effecteurs et des molecules d'arn transdominants
WO2004018681A2 (fr) * 2002-08-08 2004-03-04 Cytheris Substance de medicament a base d'il-7, composition, preparation et utilisations correspondantes
WO2009101737A1 (fr) * 2008-02-14 2009-08-20 Osaka University Vecteur d'expression de protéine marqué par un peptide ayant un résidu de méthionine
US20140377218A1 (en) * 2011-08-03 2014-12-25 Cytheris Hcv immunotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0324789B1 (fr) * 1986-10-02 2003-08-20 Massachusetts Institute Of Technology Procede de regulation de la stabilite metabolique de proteines
US5093242A (en) 1986-10-02 1992-03-03 Massachusetts Institute Of Technology Methods of generating desired amino-terminal residues in proteins
JP2501618B2 (ja) 1988-04-01 1996-05-29 三井東圧化学株式会社 有機ケイ素化合物およびその製造方法
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Ｉｌ－７ 융합 단백질
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP1746161A1 (fr) 2005-07-20 2007-01-24 Cytheris IL-7 glycosylée, préparation et utilisations
WO2007019232A2 (fr) 2005-08-03 2007-02-15 Immunogen, Inc. Formulations d'immunoconjugué
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
EP2080812A1 (fr) 2008-01-18 2009-07-22 Transmedi SA Compositions et procédés pour détecter des peptides post-stop
EP2288386A1 (fr) 2008-02-19 2011-03-02 Asterion Limited Liants modifiés
KR20090090953A (ko) 2008-02-22 2009-08-26 포항공과대학교 산학협력단 Ａｉｄｓ 예방 및 치료를 위한 ａｉｄｓ ｄｎａ백신(ｇｘ-127) 또는 재조합 아데노바이러스
WO2011088421A2 (fr) * 2010-01-15 2011-07-21 California Institute Of Technology Découverte et applications de la fonction protéolytique de l'acétylation n-terminale des protéines cellulaires
CN101942020A (zh) 2010-01-16 2011-01-12 温州医学院 链亲和素/白细胞介素7融合蛋白
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
AR086250A1 (es) 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
CN102775496B (zh) 2011-05-13 2014-10-08 中国医学科学院基础医学研究所 靶向清除hiv/siv的复合药物
WO2013074489A1 (fr) * 2011-11-14 2013-05-23 Emory University Conjugués de gm-csf et d'il-7, compositions en contenant et méthodes associées
US9803207B2 (en) 2013-07-31 2017-10-31 Biogenomics Limited Expression vector for production of recombinant proteins in prokaryotic host cells
HK1256149A1 (zh) * 2015-06-11 2019-09-13 格纳西尼有限公司 经修饰的白细胞介素-7蛋白及其用途
US11708399B2 (en) 2015-12-04 2023-07-25 Genexine, Inc. Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314415B1 (fr) * 1987-10-26 1994-08-10 Immunex Corporation Interleukine-7
EP0877752A1 (fr) * 1996-01-23 1998-11-18 The Board Of Trustees Of The Leland Stanford Junior University Procedes servant a rechercher par criblage des peptides effecteurs et des molecules d'arn transdominants
WO2004018681A2 (fr) * 2002-08-08 2004-03-04 Cytheris Substance de medicament a base d'il-7, composition, preparation et utilisations correspondantes
WO2009101737A1 (fr) * 2008-02-14 2009-08-20 Osaka University Vecteur d'expression de protéine marqué par un peptide ayant un résidu de méthionine
US20140377218A1 (en) * 2011-08-03 2014-12-25 Cytheris Hcv immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016200219A1 *

Also Published As

Publication number Publication date
WO2016200219A1 (fr) 2016-12-15
CN114853873B (zh) 2025-01-28
CA2986388A1 (fr) 2016-12-15
RU2708160C2 (ru) 2019-12-04
RU2018100181A (ru) 2019-07-16
US20190106471A1 (en) 2019-04-11
JP7087047B2 (ja) 2022-06-20
HK1256149A1 (zh) 2019-09-13
US20170158746A1 (en) 2017-06-08
JP2022130427A (ja) 2022-09-06
CN108093638A (zh) 2018-05-29
US10844104B2 (en) 2020-11-24
EP3307766A1 (fr) 2018-04-18
US11041007B2 (en) 2021-06-22
JP2018518955A (ja) 2018-07-19
KR20160146584A (ko) 2016-12-21
JP2021052772A (ja) 2021-04-08
KR101873201B1 (ko) 2018-07-02
US10208099B2 (en) 2019-02-19
KR20180069775A (ko) 2018-06-25
RU2018100181A3 (fr) 2019-07-17
US20180273596A1 (en) 2018-09-27
CN114853873A (zh) 2022-08-05
CA2986388C (fr) 2024-02-27
KR20180068938A (ko) 2018-06-22
KR101986368B1 (ko) 2019-06-05

Similar Documents

Publication Publication Date Title
IL293377A (en) Hsd17b13 variants and uses thereof
EP3707248A4 (fr) Cellules immunitaires modifiées et leurs utilisations
EP3411412A4 (fr) Technologie fit-immunoglobuline et ses utilisations
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
IL268593A (en) Polypeptide variants and uses thereof
EP3633034A4 (fr) PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
EP3413816A4 (fr) Compositions hydratantes et utilisations associées
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
PL3258951T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
MA49715A (fr) Oligomères et conjugués d'oligomères
EP2968443A4 (fr) Analogues d'hepcidine et leurs utilisations
EP3733702A4 (fr) Anticorps anti-lag-3 et utilisations associées
EP3439741A4 (fr) Antagonistes d'alk7 et leurs utilisations
EP3364958A4 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
IL271398A (en) Anti-l1-cam antibodies and uses thereof
EP3302490A4 (fr) Inhibiteurs d'autotaxine et leurs utilisations
EP3434285A4 (fr) Composition pharmaceutique et ses utilisations
EP3405044A4 (fr) Composition bioconservatrice alimentaire et ses utilisations
MA53991A (fr) Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations
EP3336170A4 (fr) Puce et son application
EP3496748A4 (fr) Anticorps anti-o2 et utilisations associées
EP3436434A4 (fr) Analogues d'indoline et leurs utilisations
MA44968A (fr) Esters d'oxaborole et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/54 20060101AFI20181213BHEP

Ipc: A61K 38/20 20060101ALI20181213BHEP

Ipc: C07K 19/00 20060101ALI20181213BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LIM, HYE SEONG

Inventor name: YANG, SE HWAN

Inventor name: CHOI, DONGHOON

Inventor name: SUNG, YOUNG CHUL

A4 Supplementary search report drawn up and despatched

Effective date: 20190515

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/54 20060101AFI20190509BHEP

Ipc: C07K 19/00 20060101ALI20190509BHEP

Ipc: A61K 38/20 20060101ALI20190509BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221121